Overview

• IRadimed Q3 revenue grows 16% yr/yr, beating analyst expectations

• Adjusted EPS for Q3 rises 9% yr/yr, reflecting operational strength

• Company raises full-year 2025 revenue and EPS guidance

Outlook

• IRadimed raises full-year 2025 revenue guidance to $82.5 mln to $83.5 mln

• Company expects Q4 2025 revenue of $21.4 mln to $22.4 mln

• IRadimed anticipates full-year 2025 GAAP EPS of $1.68 to $1.72

Result Drivers

• RECORD REVENUE - Co reports record Q3 revenue of $21.2 mln, a 16% increase yr/yr, driven by strong demand for MRI-compatible devices

• FACILITY TRANSITION - Co experienced transitional inefficiencies moving to new Orlando facility but maintained 78% gross margin

• PRODUCT BACKLOG - Co reports all-time high backlog for pump and monitor products, positioning for future demand

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for IRadimed Corp is $82.50, about 6.9% above its October 31 closing price of $76.81

• The stock recently traded at 37 times the next 12-month earnings vs. a P/E of 31 three months ago

Press Release: ID:nGNX8w0tgc

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)